Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01QKR
|
||||
| Former ID |
DIB015579
|
||||
| Drug Name |
ALNESPIRONE
|
||||
| Synonyms |
S-20499; Alnespirone < Rec INN >; (+)-(S)-N-[4-[(5-Methoxy-3-chromanyl)propylamino]butyl]-1,1-cyclopentanediacetimide; (S)-(+)-8-[4-[N-(5-Methoxy-3,4-dihydro-2H-benzo[b]pyran-3-yl)-N-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H39ClN2O4
|
||||
| Canonical SMILES |
CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@@H]3COc4cccc(OC)c4C3
|
||||
| InChI |
1S/C26H38N2O4/c1-3-13-27(20-16-21-22(31-2)9-8-10-23(21)32-19-20)14-6-7-15-28-24(29)17-26(18-25(28)30)11-4-5-12-26/h8-10,20H,3-7,11-19H2,1-2H3/t20-/m0/s1
|
||||
| InChIKey |
DLLULNTXJPATBC-FQEVSTJZSA-N
|
||||
| CAS Number |
CAS 138298-79-0
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Agonist | [2], [3] | |
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001421) | ||||
| REF 2 | Chronic alnespirone-induced desensitization of somatodendritic 5-HT1A autoreceptors in the rat dorsal raphe nucleus. Eur J Pharmacol. 1999 Jan 22;365(2-3):165-73. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.